as 07-26-2024 4:00pm EST
VBI Vaccines Inc is a commercial-stage, the biopharmaceutical company which is engaged in developing next-generation vaccines to address unmet needs in infectious disease and immuno-oncology. The company manufactures Sci-B-Vac product which is a hepatitis B (HBV) vaccine for adults, children, and newborns. Its products include Virus-Like Particle which is vaccine platform which allows for the design of enveloped virus-like particle vaccines that closely mimic the target viruses. The company operates through the single segment being Developing vaccines to address unmet needs in infectious disease and immuno-oncology.
Founded: | N/A | Country: | United States |
Employees: | N/A | City: | CAMBRIDGE |
Market Cap: | 22.6M | IPO Year: | N/A |
Target Price: | N/A | AVG Volume (30 days): | 197.6K |
Analyst Decision: | N/A | Number of Analysts: | N/A |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | -5.65 | EPS Growth: | N/A |
52 Week Low/High: | $0.45 - $1.36 | Next Earning Date: | 08-12-2024 |
Revenue: | $9,411,000 | Revenue Growth: | 553.09% |
Revenue Growth (this year): | 50.9% | Revenue Growth (next year): | 165.67% |
VBIV Breaking Stock News: Dive into VBIV Ticker-Specific Updates for Smart Investing
Business Wire
a month ago
PR Newswire
2 months ago
PR Newswire
2 months ago
GlobeNewswire
2 months ago
Simply Wall St.
2 months ago
Business Wire
2 months ago
AFP
2 months ago
Motley Fool
2 months ago
The information presented on this page, "VBIV VBI Vaccines Inc. New (Canada) - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.